Sains Malaysiana 54(7)(2025): 1835-1846
http://doi.org/10.17576/jsm-2025-5407-16

Integrating Microfluidics and 3D Bioprinting for Advanced *in vitro* Tissue and Organ Models

(Mengintegrasikan Mikrobendalir dan Pencetakan Bio 3D untuk Tisu *in vitro* dan Model Organ Termaju)

WEI FU[1], SHAHARIAR CHOWDHURY[2], SIEW XIAN CHIN[3] & ZHENYA YUAN[4,*]

[1]*Faculty of Bioscience and Bioengineering, Jiangxi Agricultural University, Nanchang, China*
[2]*Faculty of Environmental Management, Prince of Songkla University, 90110 Hatyai Songkhla, Thailand*
[3]*ASASIpintar Program, Pusat GENIUS@Pintar Negara, Universiti Kebangsaan Malaysia, 43600 UKM Bangi, Selangor, Malaysia*
[4]*Pathology Department, The First Affiliated Hospital of Hainan Medical University, Haikou, China*

Received: 17 April 2025/Accepted: 22 May 2025

ABSTRACT

Advances in tissue engineering necessitate *in vitro* models that accurately replicate human organ complexity. The limitations of conventional 2D cultures and animal models have driven development of biomimetic platforms integrating microfluidics and 3D bioprinting. Microfluidic technologies enable precise control of fluid dynamics, nutrient delivery, and biochemical gradients at microscale, while 3D bioprinting facilitates layer-by-layer fabrication of complex tissue structures. This review examines design principles of microfluidic platforms, highlighting organ-on-a-chip and tumor-on-a-chip applications demonstrating controlled perfusion advantages. We analyze major bioprinting modalities, extrusion, inkjet, laser-assisted, and stereolithography, evaluating their suitability for specific tissue engineering applications. The review describes integration strategies, including direct cell bioprinting into microfluidic channels and using microfluidic molds for bioprinted constructs, which enhance vascularization and perfusion. We explore bioink advancements focusing on printability, mechanical properties, and stimulus-responsiveness (4D bioprinting). Finally, we address critical research directions: resolution enhancement, hierarchical vascular network development, AI-driven optimization, and regulatory standardization to facilitate clinical translation. This synthesis of current achievements and future directions aims to guide development of sophisticated *in vitro* models for disease modeling, drug discovery, and personalized medicine.

Keywords: Biomimetic models; microfluidics; organ-on-a-chip; tissue engineering; 3D bioprinting

ABSTRAK

Kemajuan dalam kejuruteraan tisu memerlukan model *in vitro* yang mereplikasi kerumitan organ manusia dengan tepat. Keterbatasan kultur 2D konvensional dan model haiwan telah mendorong pembangunan platform biomimetik yang menyepadukan mikrobendalir dan pencetakan bio 3D. Teknologi mikrobendalir membolehkan kawalan tepat ke atas dinamik bendalir, penghantaran nutrien dan kecerunan biokimia pada skala mikro, manakala pencetakan bio 3D memudahkan fabrikasi lapisan demi lapisan bagi struktur tisu kompleks. Penyelidikan ini mengkaji prinsip reka bentuk platform mikrobendalir, menyerlahkan aplikasi *organ-on-a-chip* dan *tumor-on-a-chip* yang menunjukkan kelebihan perfusi terkawal. Kami menganalisis modaliti pencetakan bio utama, penyemperitan, pancutan dakwat, bantuan laser dan stereolitografi, menilai kesesuaiannya untuk aplikasi kejuruteraan tisu tertentu. Penyelidikan ini menerangkan strategi penyepaduan, termasuk pencetakan bio sel terus ke dalam saluran mikrobendalir dan menggunakan acuan mikrobendalir untuk binaan biocetak yang meningkatkan vaskularisasi dan perfusi. Kami meneroka kemajuan dakwat bio yang memfokuskan pada kebolehcetakan, sifat mekanikal dan tindak balas rangsangan (percetakan bio 4D). Akhir sekali, kami menangani arah penyelidikan kritikal: peningkatan resolusi, pembangunan rangkaian vaskular hierarki, pengoptimuman dipacu AI dan penyeragaman kawal selia untuk memudahkan terjemahan klinikal. Sintesis pencapaian semasa dan hala tuju masa hadapan ini bertujuan untuk membimbing pembangunan model *in vitro* yang canggih untuk pemodelan penyakit, penemuan ubat dan perubatan yang diperibadikan.

Kata kunci: Kejuruteraan tisu; mikrobendalir; model biomimetik; *organ-on-a-chip*; pencetakan bio 3D

INTRODUCTION

THE CRITICAL NEED FOR ADVANCED *in vitro* MODELS

The increasing global prevalence of diseases such as kidney failure poses significant healthcare challenges worldwide (Yi, Lee & Cho 2017). Chronic kidney disease (CKD), characterized by progressive loss of kidney function, affects millions of people globally, creating an urgent demand for effective treatments (Christou et al. 2023). However, current therapeutic options, including dialysis and kidney transplantation, are limited by factors such as organ donor scarcity, rejection risks, and high treatment costs, highlighting an urgent need for alternative approaches (Peired et al. 2020).

Advanced *in vitro* models have become critical tools to overcome these limitations, enabling precise studies of biological processes, disease mechanisms, and treatment responses. Unlike traditional approaches, advanced *in vitro* systems accurately replicate complex physiological conditions, enhancing our understanding of human biology (Yi, Lee & Cho 2017). These platforms streamline drug discovery by predicting therapeutic efficacy and toxicity earlier, thus, reducing clinical trial failures and supporting personalized medicine through patient-specific modeling (Yao et al. 2020).

Microfluidics and 3D bioprinting technologies further enhance these models. Microfluidics precisely controls cellular environments, closely mimicking physiological conditions (Casanova et al. 2024), while 3D bioprinting enables accurate fabrication of multi-cellular tissue architectures and functionalities (Klangprapan, Souza & Ferreira 2024). Integrated, these technologies significantly advance the biomimicry of *in vitro* models, addressing limitations of current therapies and improving outcomes for diseases such as kidney failure.

SHORTCOMINGS OF CONVENTIONAL 2D CULTURES AND ANIMAL MODELS

Conventional 2D cultures and animal models are limited in accurately replicating human physiological and pathological conditions (Serrano et al. 2023). Traditional 2D cell cultures fail to capture the complex three-dimensional tissue architectures, spatial arrangements, and mechanical properties of native tissues, causing altered cell behavior and functionality (Kahraman et al. 2022). Consequently, critical cellular processes such as differentiation, proliferation, and drug responses are inadequately represented.

Animal models, though informative, inherently differ from human physiology, reducing experimental reliability and clinical translation (Rothbauer et al. 2021). Interspecies variations can cause discrepancies in disease progression, therapeutic responses, and toxicological outcomes. For instance, conventional models inadequately replicate the complexity of the renal glomerulus or the dynamic, branched microenvironments of salivary glands (Peired et al. 2020; Rothbauer et al. 2021). These limitations highlight the critical need for advanced *in vitro* models capable of closely mimicking human tissue complexity and dynamics.

THE ADVENT OF MICROFLUIDICS AND 3D BIOPRINTING AS TRANSFORMATIVE TOOLS

The advent of microfluidics and 3D bioprinting technologies has transformed *in vitro* model development. Microfluidic systems precisely control fluid flow (Peired et al. 2020), biochemical gradients (De Spirito et al. 2024), and mechanical stimuli at the microscale (Yi, Lee & Cho 2017). This accuracy replicates dynamic physiological environments, promoting natural cellular behavior, and supports high-throughput, cost-efficient analysis using minimal reagents and cells (Garg et al. 2016).

3D bioprinting complements microfluidics by fabricating complex, multi-cellular constructs with precise spatial control. It enables the recreation of intricate tissue architectures, including vascular networks crucial for tissue viability (De Spirito et al. 2024). By depositing biomaterials and cells layer-by-layer, 3D bioprinting closely replicates native organ structures and functions. Combined, these technologies enhance *in vitro* models, advancing biomedical research, drug discovery, and personalized medicine (Miri et al. 2019).

SYNERGISTIC POTENTIAL: CONVERGENCE FOR ENHANCED BIOMIMICRY

The integration of microfluidics and 3D bioprinting offers significant synergistic advantages for advanced biomimicry. Individually, microfluidics precisely controls fluid flow and biochemical gradients but struggles with constructing complex, densely cellularized, three-dimensional tissue architectures (Zaeri et al. 2022). Conversely, 3D bioprinting accurately fabricates intricate tissue structures but faces challenges replicating dynamic physiological environments required for tissue maturation (Christou et al. 2023).

Combining these technologies effectively addresses their respective limitations. Microfluidics supports bioprinted tissues through continuous nutrient supply and waste removal, simulating physiological conditions and facilitating complex vasculature formation (Muniraj et al. 2023). Integrated systems have successfully replicated kidney glomerular function (Klangprapan, Souza & Ferreira 2024) and complex branched structures of salivary glands (Rose et al. 2024). Thus, merging microfluidics with bioprinting enhances physiological relevance, enabling sophisticated models that closely mimic human tissues and organs (Ma, Wang & Liu 2018).

SCOPE AND OBJECTIVES OF THIS REVIEW

This review focuses on recent advances integrating microfluidics and 3D bioprinting technologies for advanced *in vitro* tissue and organ models. We provide

a concise overview of current methodologies in this interdisciplinary field, highlighting key achievements such as functional vascularized tissues, organ-specific models, and biomimetic tumor microenvironments. Additionally, we discuss current limitations and propose future research directions. By summarizing recent findings and emerging trends, this review aims to serve as a valuable resource for researchers and clinicians, facilitating translation into biomedical research, drug discovery, and personalized medicine.

MICROFLUIDIC PLATFORMS FOR CONTROLLED CELLULAR MICROENVIRONMENTS

FUNDAMENTAL PRINCIPLES AND ADVANTAGES

Microfluidics precisely manipulates small fluid volumes within microchannels, creating controlled microscale environments for cellular studies (Cao et al. 2023). At this scale, fluid flow is laminar, allowing predictable and accurate fluid dynamics. Precise control of fluid flow, biochemical gradients, and mechanical forces enables faithful replication of physiological microenvironments (Jeon, Sorrells & Abaci 2022).

Stable biochemical gradients of growth factors, nutrients, and chemokines can be maintained, guiding cell migration, proliferation, and differentiation similarly to *in vivo* conditions (Casanova et al. 2024). Additionally, microfluidics precisely regulates mechanical stimuli such as shear stress and stretch forces, essential for modeling dynamic conditions like vascular flow and tissue deformation (Davoodi et al. 2020).

The miniaturization of microfluidics significantly reduces reagent consumption, improving cost-effectiveness and sustainability (Shiwarski et al. 2024). Confined microenvironments enhance cell-cell and cell-matrix interactions, promoting physiologically relevant behaviors (Michas et al. 2025). Furthermore, microfluidics supports high-throughput screening, enabling rapid and reliable data collection crucial for drug discovery, toxicology, and personalized medicine (Serrano et al. 2023).

MATERIALS AND FABRICATION TECHNIQUES FOR MICROFLUIDIC DEVICES

Microfluidic devices commonly utilize biocompatible materials like polydimethylsiloxane (PDMS), valued for its optical transparency, gas permeability, flexibility, ease of fabrication, and biocompatibility (McDonald & Whitesides 2002). PDMS supports effective cell culture, microscopy, and biochemical analysis, facilitating diverse biomedical applications including tissue engineering and disease modeling.

Photolithography remains fundamental for device fabrication, involving selective ultraviolet exposure of photoresist through patterned masks to define precise microscale channel geometries (Fang et al. 2022). Soft lithography with PDMS molds enables reproducible production of microchannels tailored for specific biological applications (Zhou et al. 2022). Recently, additive manufacturing methods like melt extrusion additive manufacturing (MEAM) have emerged, allowing rapid prototyping and increased design flexibility for complex three-dimensional channel geometries unattainable by traditional methods (Moetazedian et al. 2023).

KEY APPLICATIONS IN ENGINEERING *in vitro* MODELS

Organ-on-a-Chip (OoC) Systems

Organ-on-a-chip (OoC) platforms replicate the microscale structure, function, and microenvironment of human organs by integrating human cells within engineered microchannels. OoCs accurately model tissue architecture, cellular interactions, and physiological responses, surpassing conventional culture methods (Baptista et al. 2022).

Kidney-on-a-chip models, featuring epithelial-lined microchannels, replicate renal filtration, reabsorption, and secretion processes, making them valuable for nephrotoxicity assessment, drug transport studies, and renal disease modeling (Peired et al. 2020). Similarly, heart-on-a-chip systems incorporate cardiomyocytes into microfluidic channels to emulate synchronized contractions and physiological responses, providing robust platforms for cardiotoxicity screening and personalized medicine (Rothbauer et al. 2021). Together, these OoC systems significantly advance biomedical research, drug development, and personalized therapies by closely mimicking human organ complexity.

Tumor-on-a-Chip

Tumor-on-a-chip platforms are advanced microfluidic systems designed to model the complexity of the tumor microenvironment (TME), including cellular heterogeneity, extracellular matrix interactions, biochemical gradients, and mechanical stresses (Fang et al. 2022). These systems enable cancer biology studies at single-cell resolution, improving the accuracy of drug efficacy predictions, drug resistance understanding, and identification of personalized therapies (Kim et al. 2023).

Additionally, tumor-on-a-chip models effectively study metastasis by replicating tumor invasion, intravasation, and extravasation within controlled microscale environments. Incorporating endothelial cells, stromal cells, and extracellular matrix components, these models offer physiologically relevant conditions to investigate cancer cell migration, angiogenesis, and TME interactions, providing crucial insights into metastatic mechanisms and potential therapeutic strategies (Chliara, Elezoglou & Zergioti 2022).

Vascularization Studies

Microfluidic technologies significantly advance vascular biology research by enabling precise engineering of

microvascular networks. These platforms replicate key aspects of vessel formation, remodeling, and stabilization, facilitating detailed angiogenesis studies (Ma, Wang & Liu 2018). Precise control of biochemical gradients like VEGF directs endothelial cell sprouting, lumen formation, and maturation, allowing investigation of angiogenic signaling pathways and cellular interactions under physiological conditions (Kim et al. 2016).

Microfluidic models also support targeted drug delivery research by accurately mimicking vessel permeability, fluid dynamics, and tissue-specific barriers (Deosarkar et al. 2015). For instance, blood-brain barrier (BBB) models integrating brain endothelial cells, astrocytes, and pericytes closely capture barrier functionality. These systems enable studies on drug permeability (Park et al. 2019), neuroinflammation (Herland et al. 2016), and barrier disruption (Terrell-Hall et al. 2017), improving therapeutic approaches and drug screening accuracy. Overall, microfluidic vascularization platforms significantly enhance understanding of vascular physiology, angiogenesis, and drug delivery.

Drug Testing and Toxicology

Microfluidic platforms significantly advance drug testing and toxicology by enabling precise pharmacokinetic (PK) and pharmacodynamic (PD) studies within controlled microscale environments (Skardal et al. 2015). These systems replicate fluid flow and tissue barriers to accurately model drug absorption, distribution, metabolism, and elimination, allowing detailed assessment of therapeutic efficacy at cellular and organ levels.

Organ-specific toxicity evaluations have notably benefited from these platforms. Liver-on-a-chip models simulate hepatic metabolism, enabling earlier, reliable detection of hepatotoxicity compared to traditional methods (Ewart et al. 2022). Heart-on-a-chip systems replicate physiological cardiac stresses, facilitating accurate evaluation of cardiotoxic effects (Gu et al. 2024). Kidney-on-a-chip platforms model renal filtration barriers to precisely assess nephrotoxicity, enhancing clinical predictability and patient safety (Petrosyan et al. 2019). Thus, microfluidics substantially improves drug safety evaluations and personalized therapeutic approaches.

Periodontal Research

Microfluidic organ-on-a-chip (OoC) platforms have recently advanced periodontal research by enabling detailed study of complex oral tissues, such as the periodontium, which comprises gingival tissues, periodontal ligament, cementum, and alveolar bone (Muniraj et al. 2023). These platforms precisely replicate the dynamic periodontal microenvironment, including cellular interactions, mechanical forces, and biochemical gradients, allowing studies of tissue regeneration, inflammation, microbial-host interactions, and responses to therapies (Huang et al. 2023). Gingiva-on-chip models, for example, have provided insights into epithelial barrier function and host-microbe interactions, significantly enhancing understanding of periodontal health and disease mechanisms (Makkar et al. 2023).

3D BIOPRINTING: FABRICATION OF COMPLEX TISSUE ARCHITECTURES

CORE PRINCIPLES OF ADDITIVE MANUFACTURING IN BIOLOGY

3D bioprinting is an additive manufacturing technique that fabricates complex biological structures by precise, layer-by-layer deposition of biomaterials and living cells. Unlike traditional methods, which remove material to shape structures, bioprinting sequentially deposits bioinks - cell-containing hydrogels or extracellular matrix components - to create spatially defined tissues (Murphy & Atala 2014).

Bioprinting employs computer-aided design (CAD) to define tissue architectures, followed by controlled bioink deposition through specialized printers. This process allows precise placement of various cell types and biomaterials, closely replicating native cellular organization and extracellular environments. Parameters such as extrusion speed, temperature, and crosslinking conditions are finely tuned to maintain structural integrity and functionality (Yi, Lee & Cho 2017).

Through systematic layering, bioprinting enables fabrication of intricate structures like vascular networks, branched ducts, and heterogeneous cellular arrangements, significantly advancing tissue engineering, regenerative medicine, and personalized therapies (Fang et al. 2022).

MAJOR BIOPRINTING MODALITIES AND THEIR CHARACTERISTICS

The creation of three-dimensional biological constructs through bioprinting involves several distinct modalities, each employing different bioink dispensing methods. As illustrated in Figure 1, these include extrusion-based bioprinting, which continuously dispenses cell-laden bioinks using pneumatic or mechanical pressure; inkjet bioprinting, known for precise droplet deposition; and laser-assisted and stereolithography bioprinting, both utilizing focused light energy to solidify or transfer biomaterials selectively. Understanding these techniques and their characteristics is essential for appreciating the capabilities and limitations of bioprinting technologies in fabricating intricate biological structures.

Extrusion-Based Bioprinting

Extrusion-based bioprinting creates three-dimensional biological constructs by continuously dispensing bioinks composed of cell-laden hydrogels through a nozzle, forming precise spatial structures layer-by-layer (Figure 1(a)). Driven by pneumatic pressure or mechanical

force, it allows accurate control over bioink deposition, printing speed, and resolution (Davoodi et al. 2020). This versatile method effectively fabricates complex tissue architectures such as vascular networks and branched tubular structures essential for nutrient and oxygen delivery (Wu et al. 2021). Its simplicity and adaptability make it valuable for tissue engineering and regenerative medicine, closely replicating native tissues including blood vessels and glandular ducts (Hinton et al. 2025).

Inkjet Bioprinting

Inkjet bioprinting is a droplet-based bioprinting technique that precisely deposits bioinks onto substrates in a layer-by-layer manner (Figure 1(b)). Similar to conventional inkjet printing, this modality uses thermal or piezoelectric mechanisms to generate droplets containing cells suspended in bioinks. These droplets are accurately placed, allowing precise spatial positioning of cells and biomaterials within tissue constructs (Chliara, Elezoglou & Zergioti 2022). A primary advantage of inkjet bioprinting is its capability for high-resolution deposition, facilitating precise patterning of multiple cell types and biomaterials with excellent spatial control. Due to its gentle printing conditions, this approach maintains high cell viability, making it suitable for applications requiring delicate handling of sensitive cell populations (Zhou et al. 2022). Inkjet bioprinting is widely used for fabricating tissue models that demand precise cellular organization, such as skin, cartilage, and intricate cell patterning within microarrays (Kim et al. 2017).

Laser-Assisted Bioprinting

Laser-assisted bioprinting represents a high-resolution, nozzle-free approach that utilizes laser energy to precisely deposit bioinks. In this modality, a pulsed laser irradiates a donor layer (typically a gold or titanium ribbon coated with bioink), generating vapor bubbles that propel droplets onto a receiving substrate (Figure 1(c)) (Vinson, Sklare & Chrisey 2017). This technique achieves exceptional resolution (10-50 μm) and cell viability (>95%), as it avoids shear stresses inherent to extrusion or inkjet methods (Lam et al. 2023). Laser-assisted bioprinting excels in patterning delicate cell types, such as primary neurons or stem cells, with single-cell precision, critical for neural networks or stem cell niche engineering (Zhang et al. 2021). Recent advances include dynamic optical systems that enable non-planar printing of curved tissues (corneal layers) and multi-material deposition by sequential laser pulses (Jia et al. 2023). However, Laser-assisted bioprinting faces challenges in scalability due to slow printing speeds and the high cost of laser systems (Ventura 2021).



FIGURE 1. Illustration of the core mechanisms underlying (a) Extrusion-based, (b) Inkjet, (c) Laser-assisted bioprinting, and (d) Stereolithography, representing the major modalities in the field

Stereolithography

Stereolithography (SLA) employs ultraviolet (UV) or visible light to photopolymerize bioinks layer-by-layer within a vat of photoactive hydrogel (Figure 1(d)). Digital light processing (DLP), a variant of SLA, projects patterned light to solidify entire layers simultaneously, drastically reducing print times (Melchels, Feijen & Grijpma 2010). SLA achieves resolutions down to 25 μm, surpassing extrusion-based methods, and supports bioinks with low viscosity (gelatin methacryloyl (GelMA) and polyethylene glycol diacrylate (PEGDA)), which are unsuitable for extrusion (Lim et al. 2018). A landmark innovation is the use of support baths (FRESH printing), where bioinks are printed into a temporary gel matrix to prevent collapse during curing (Hinton et al. 2025). SLA's precision is ideal for complex microarchitectures, however, UV exposure risks DNA damage, necessitating careful optimization of photoinitiators and exposure durations (Lin et al. 2013).

SYNERGISTIC INTEGRATION: MICROFLUIDICS AND 3D BIOPRINTING FOR ADVANCED MODELS

RATIONALE FOR COMBINING TECHNOLOGIES

Integrating microfluidics with 3D bioprinting combines precise cellular microenvironment control with the capability to create complex biological structures. Microfluidics enables defined control of fluid flow, biochemical gradients, and mechanical stimuli, crucial for maintaining cell viability and promoting physiologically relevant behavior (Rothbauer et al. 2022). Coupled with 3D bioprinting's spatial accuracy, this integration allows the construction of sophisticated tissues directly within microfluidic channels, facilitating continuous perfusion for nutrient delivery, oxygenation, and waste removal (Davoodi et al. 2020). Such platforms significantly enhance tissue maturation and functional relevance, overcoming individual technology limitations and advancing biomedical research, disease modeling, drug screening, and regenerative medicine (Ozbolat & Hospodiuk 2016).

DIVERSE STRATEGIES FOR INTEGRATION

Microfluidics and 3D bioprinting integration employs multiple strategies. One approach involves directly bioprinting bioinks within prefabricated microfluidic channels, ensuring precise spatial organization and controlled microenvironments, suitable for vascular and tubular tissue constructs (Zhang et al. 2016). Alternatively, bioprinted tissues can interconnect with microfluidic channels, forming hybrid vascular networks that support continuous perfusion, enhancing the viability of thicker constructs (Pi et al. 2018). Microfluidic devices may also serve as molds or templates to shape bioink deposition, creating precise microtubes, microfibers, or complex architectures. Once crosslinked, the template is removed, leaving biomimetic tissues with accurate morphology (Costantini et al. 2017).

ILLUSTRATIVE EXAMPLES OF INTEGRATED SYSTEMS FOR VASCULARIZED ORGAN SYSTEMS

Developing vascularized organ models significantly enhances organ-on-a-chip (OoC) and tissue engineering platforms. Integrating vascular networks ensures efficient nutrient delivery, oxygenation, and waste removal, critical for viability in thick tissues exceeding diffusion limits (Kolesky et al. 2016). Functional vasculature also allows accurate modeling of physiological complexities such as angiocrine signaling, immune interactions, and drug responses. Advanced approaches leveraging combined microfluidics and bioprinting technologies enable sophisticated engineering of vascular structures (Hinton et al. 2025; Wu et al. 2021).

ADVANCEMENTS IN BIOMATERIALS AND BIOINKS TAILORED FOR INTEGRATED PLATFORMS

MATERIAL PROPERTY CONSIDERATIONS

Successful integration of microfluidics and 3D bioprinting relies heavily on biomaterial selection. Key considerations include biocompatibility (Kim, Lee & Kim 2016), suitable mechanical properties (Wang, Gust & Ferrell 2022), controlled degradation rates (Wu et al. 2022), and compatibility with microfluidic device materials. Common hydrogels such as gelatin methacryloyl (GelMA), collagen, and alginate are favored due to their extracellular matrix-mimicking properties, promoting essential cellular functions (Klotz et al. 2016). Mechanical properties, including viscosity and elasticity, directly affect bioink printability and cellular behavior post-printing (Marcotulli et al. 2023). Additionally, controlled biomaterial degradation supports tissue remodeling, matching natural regeneration timelines (Wu et al. 2022). Finally, compatibility between biomaterials and microfluidic materials like PDMS and thermoplastics is critical to ensure long-term device stability and performance (Chliara, Elezoglou & Zergioti 2022).

DEVELOPMENT OF ADVANCED BIOINKS WITH ENHANCED FUNCTIONALITY

Recent advances in bioink development have significantly improved microfluidic-bioprinting capabilities. Enhanced printability is achieved through optimization of bioink rheology, ensuring smooth deposition and structural fidelity (Moghimi et al. 2023). Bioinks such as gelatin methacryloyl (GelMA) (Liu et al. 2020), alginate blends (Li et al. 2020), and collagen formulations (Kim, Lee & Kim 2016) offer consistent extrusion and rapid stabilization post-printing (Fratini et al. 2023). Modern bioinks incorporate bioactive components like growth factors and adhesion peptides to improve cellular viability, attachment, and proliferation, thereby supporting long-term tissue maturation (Pi et al. 2018). Multi-component bioinks also enable precise spatial positioning of multiple cell types, crucial for replicating tissue complexity such as vascular networks and tumor

microenvironments (Fang et al. 2022). Moreover, stimuli-responsive ('smart') bioinks dynamically respond to environmental triggers, facilitating post-printing tissue remodeling and enhanced functionality (Ionov 2018).

MULTI-MATERIAL AND MULTI-CELLULAR PRINTING WITHIN MICROFLUIDIC ENVIRONMENTS

Integrated microfluidic-bioprinting platforms have advanced multi-material and multi-cellular bioprinting capabilities, enabling highly biomimetic tissue models. Techniques such as gradient-based bioprinting utilize microfluidic printheads to control cell density and biochemical cue gradients dynamically, replicating physiological tissue transitions found in cartilage or vascularized constructs (Cardoso et al. 2023). Layer-by-layer deposition further allows precise three-dimensional arrangements of distinct cell types and biomaterials, essential for fabricating stratified tissues such as skin or organ-specific zonation (Ozbolat & Hospodiuk 2016). Moreover, simultaneous multi-channel microfluidic printing facilitates heterogeneous tissue constructs, accurately reflecting native tissue complexity (Miri et al. 2019). These strategies collectively enhance the physiological relevance and translational potential of engineered tissues, significantly advancing tissue engineering and regenerative medicine.

FUTURE DIRECTIONS AND CONCLUSIONS

Integrating microfluidics with 3D bioprinting has substantially advanced *in vitro* tissue and organ modeling. However, fully harnessing its potential requires addressing key challenges: improving bioprinting resolution, developing responsive biomaterials, scaling vascularization, leveraging artificial intelligence (AI), and establishing robust regulatory frameworks. Overcoming these limitations will lead to clinically relevant, sophisticated engineered tissues, significantly enhancing their translational impact in healthcare.

HIGH-RESOLUTION MULTI-MATERIAL BIOPRINTING

Advances in 3D bioprinting are increasingly focused on pushing spatial resolution to the cellular and even subcellular scale (<5 μm). Achieving such fine resolution is crucial for reproducing the intricate microarchitecture of tissues – for example, fabricating engineered capillary networks (~5–10 μm lumen) to support perfusion, or guiding neuron connections at the scale of synaptic junctions (on the order of 1 μm). Conventional bioprinting techniques (extrusion, inkjet) typically produce features on the order of tens to hundreds of microns, far above these native size scales (Wu, Zhu & Woo 2023). This mismatch limits the ability to recapitulate physiological cell–cell interactions and mass transfer in engineered constructs. Thus, a new generation of 'high-definition' bioprinting methods has emerged to break the resolution barrier (Zandrini et al. 2023). Notably, researchers note that native tissue anatomy demands a minimum resolution of ~5–10 μm to mimic the smallest functional units (Wu, Zhu & Woo 2023). The push for higher resolution stems from the need to fabricate hierarchical vascular networks down to capillaries (the smallest vessels are ~5-10 μm) (Corbett, Olszewski & Stevens 2019), as well as to eventually reproduce neural microcircuits where synapses occur at sub-micron scales. Recent progress indicates that subcellular feature sizes are becoming attainable, opening the door to biofabrication of tissue architectures with unprecedented detail.

DYNAMIC AND RESPONSIVE SYSTEMS (4D BIOPRINTING)

4D bioprinting leverages stimuli-responsive biomaterials, such as temperature-, pH-, or light-sensitive hydrogels, to enable post-printing shape or functional changes in tissue constructs (Miao et al. 2017). By reacting to internal or external triggers, these constructs can self-morph, fold, or degrade over time, closely mirroring native tissue behaviors like growth and remodeling (Kirillova & Ionov 2019). For instance, thermoresponsive hydrogels may transform into vascular grafts after implantation, allowing real-time self-assembly and improved integration (Zhang et al. 2023).

In addition to temperature-sensitive polymers, pH- and photoresponsive materials permit fine control over scaffold architecture and mechanical properties. Their ability to release growth factors or other bioactive agents in a spatially and temporally directed manner makes them particularly valuable for *in vitro* disease modeling and *in vivo* tissue repair (Tibbits 2014). Coupling 4D biomaterials with microfluidic systems can further enhance dynamic regulation, offering precisely timed deformations or staged release of therapeutic molecules to replicate complex physiological processes. Ultimately, these time-evolving, shape-shifting approaches expand the potential of tissue engineering, driving more realistic disease models, customizable implants, and translational applications in regenerative medicine.

VASCULARIZATION AND PERFUSION AT SCALE

Scaling perfused constructs to organ-sized dimensions requires sophisticated approaches to hierarchical vascular networks. Strategies such as sacrificial bioprinting and *in situ* endothelialization must be refined to handle multiple length scales, from large feeding vessels to microcapillaries (Kolesky et al. 2016). Advanced coaxial printing and embedded bioprinting enable precisely tuned lumen sizes and branching patterns, while bioactive coatings or growth-factor-loaded bioinks support rapid endothelial cell adhesion and vessel maturity (Kang et al. 2016). Achieving stable perfusion also depends on controlling shear stress, nutrient gradients, and flow dynamics, ensuring tight integration of vascular channels with surrounding tissue. Together, these techniques promise more physiologically relevant *in vitro* models and clinically viable implants.

AI-DRIVEN DESIGN AND AUTOMATION

Integrating AI and machine learning (ML) approaches into 3D bioprinting offers powerful tools to optimize processes, boost reproducibility, and reduce trial-and-error inefficiencies. For example, ML algorithms can systematically analyze vast datasets on bioink rheology, cell viability, and mechanical properties to refine print settings, ensuring reliable constructs and higher throughput in tissue fabrication (Sun et al. 2023). In parallel, automated systems featuring integrated sensor feedback and robotic control can monitor printing fidelity and cell behavior in real time, adjusting extrusion rates, perfusion flows, or crosslinking parameters dynamically (Moetazedian et al. 2023).

By coupling these data-driven insights with high-throughput screening, researchers can rapidly test multiple conditions, bioink compositions, growth factor doses, or microfluidic flow rates, across a single platform. This accelerates drug discovery efforts, allowing *in vitro* models to be fine-tuned for specific disease states or patient-derived cells. Moreover, AI-guided design paves the way for personalized tissue engineering: automated prediction models can suggest scaffold architectures and biomaterial formulations tailored to individual clinical needs. As these strategies mature, we can anticipate closed-loop systems that continually sense, learn, and adapt to manufacturing processes, fostering more efficient and personalized applications in regenerative medicine and beyond.

REGULATORY AND STANDARDIZATION FRAMEWORKS

Ensuring consistent standards for bioink safety, device sterility, and model validation is central to translating bioprinted systems into clinical practice (Monzón et al. 2015). These frameworks help guarantee reproducibility, patient safety, and comparability across laboratories and commercial entities. Beyond basic material and product testing, collaborative efforts, similar to the FDA's Organs-on-Chip program, provide unified guidelines to assess emerging technologies, bridging the gap between academic research and large-scale applications (Ewart et al. 2022). Clear regulatory pathways for novel biomaterials, multi-material printing processes, and integrated microfluidic–bioprinting platforms will be essential in harmonizing protocols globally, paving the way for accelerated clinical adoption of advanced *in vitro* models and tissue-engineered constructs.

CONCLUSIONS

The integration of microfluidics and 3D bioprinting has significantly transformed the landscape of *in vitro* tissue and organ modeling. Through precise spatial control and dynamic manipulation of the cellular microenvironment, these combined technologies have overcome fundamental limitations associated with conventional 2D cultures and animal models. The ability to replicate complex tissue architecture, cellular heterogeneity, and dynamic physiological conditions has led to significant advancements in organ-on-a-chip systems, tumor models, and vascularized tissues. These advanced platforms have already enhanced drug discovery, toxicological assessments, and personalized medicine strategies.

However, despite considerable progress, several critical areas require further innovation. Achieving higher resolution bioprinting, advancing dynamic 4D bioprinting systems, scaling vascularization strategies, integrating AI-driven automation, and establishing robust regulatory frameworks remain essential challenges. Addressing these frontiers will further enhance the physiological relevance, functionality, and clinical applicability of engineered tissues. Moving forward, continuous interdisciplinary collaboration and technological refinement will be pivotal in fully realizing the transformative potential of these advanced *in vitro* modeling techniques, ultimately driving breakthroughs in biomedical research and healthcare outcomes.

REFERENCES

Baptista, L.S., Porrini, C., Kronemberger, G.S., Kelly, D.J. & Perrault, C.M. 2022. 3D Organ-on-A-chip: The convergence of microphysiological systems and organoids. *Frontiers in Cell and Developmental Biology* 10: 1043117. https://doi.org/10.3389/fcell.2022.1043117

Cao, U.M.N., Zhang, Y., Chen, J., Sayson, D., Pillai, S. & Tran, S.D. 2023. Microfluidic Organ-on-A-chip: A guide to biomaterial choice and fabrication. *International Journal of Molecular Sciences* 24(4): 3232. https://doi.org/10.3390/ijms24043232

Cardoso, B.D., Castanheira, E.M.S., Lanceros-Méndez, S. & Cardoso, V.F. 2023. Recent advances on cell culture platforms for *in vitro* drug screening and cell therapies: From conventional to microfluidic strategies. *Advanced Healthcare Materials* 12(18): e202202936. https://doi.org/10.1002/adhm.202202936

Casanova, C.R., Casanova, M.R., Reis, R.L. & Oliveira, J.M. 2024. Advancing diagnostics and disease modeling: Current concepts in biofabrication of soft microfluidic systems. *In Vitro Models* 3(2-3): 139-150. https://doi.org/10.1007/s44164-024-00072-5

Chliara, M.A., Elezoglou, S. & Zergioti, I. 2022. Bioprinting on Organ-on-Chip: Development and applications. *Biosensors* 12(12): 1135. https://doi.org/10.3390/bios12121135

Christou, C.D., Vasileiadou, S., Sotiroudis, G. & Tsoulfas, G. 2023. Three-dimensional printing and bioprinting in renal transplantation and regenerative medicine: Current perspectives. *Journal of Clinical Medicine* 12(20): 6520. https://doi.org/10.3390/jcm12206520

Corbett, D.C., Olszewski, E. & Stevens, K. 2019. A FRESH take on resolution in 3D bioprinting. *Trends in Biotechnology* 37(11): 1153-1155. https://doi.org/https://doi.org/10.1016/j.tibtech.2019.09.003

Costantini, M., Testa, S., Mozetic, P., Barbetta, A., Fuoco, C., Fornetti, E., Tamiro, F., Bernardini, S., Jaroszewicz, J., Święszkowski, W., Trombetta, M., Castagnoli, L., Seliktar, D., Garstecki, P., Cesareni, G., Cannata, S., Rainer, A. & Gargioli, C. 2017. Microfluidic-enhanced 3D bioprinting of aligned myoblast-laden hydrogels leads to functionally organized myofibers *in vitro* and *in vivo*. *Biomaterials* 131: 98-110. https://doi.org/10.1016/j.biomaterials.2017.03.026

Davoodi, E., Sarikhani, E., Montazerian, H., Ahadian, S., Costantini, M., Swieszkowski, W., Willerth, S., Walus, K., Mofidfar, M., Toyserkani, E., Khademhosseini, A. & Ashammakhi, N. 2020. Extrusion and microfluidic-based bioprinting to fabricate biomimetic tissues and organs. *Advanced Materials Technologies* 5(8): 1901044. https://doi.org/10.1002/admt.201901044

Deosarkar, S.P., Prabhakarpandian, B., Wang, B., Sheffield, J.B., Krynska, B. & Kiani, M.F. 2015. A novel dynamic neonatal blood-brain barrier on a chip. *PLoS ONE* 10(11): e0142725. https://doi.org/10.1371/journal.pone.0142725

De Spirito, M., Palmieri, V., Perini, G. & Papi, M. 2024. Bridging the gap: Integrating 3D bioprinting and microfluidics for advanced multi-organ models in biomedical research. *Bioengineering* 11(7): 664. https://doi.org/10.3390/bioengineering11070664

Ewart, L., Apostolou, A., Briggs, S.A., Carman, C.V., Chaff, J.T., Heng, A.R., Jadalannagari, S., Janardhanan, J., Jang, K-J., Joshipura, S.R., Kadam, M.M., Kanellias, M., Kujala, V.J., Kulkarni, G., Le, C.Y., Lucchesi, C., Manatakis, D.V., Maniar, K.K., Quinn, M.E., Ravan, J.S., Rizos, A.C., Sauld, J.F.K., Sliz, J.D., Tien-Street, W., Trinidad, D.R., Velez, J., Wendell, M., Irrechukwu, O., Mahalingaiah, P.K., Ingber, D.E., Scannell, J.W. & Levner, D. 2022. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. *Communications Medicine* 2: 154. https://doi.org/10.1038/s43856-022-00209-1

Fang, L., Liu, Y., Qiu, J. & Wan, W. 2022. Bioprinting and its use in tumor-on-a-chip technology for cancer drug screening: A review. *International Journal of Bioprinting* 8(4): 46-64. https://doi.org/10.18063/ijb.v8i4.603

Fratini, C., Weaver, E., Moroni, S., Irwin, R., Dallal Bashi, Y.H., Uddin, S., Casettari, L., Wylie, M.P. & Lamprou, D.A. 2023. Combining microfluidics and coaxial 3D-bioprinting for the manufacturing of diabetic wound healing dressings. *Biomaterials Advances* 153: 213557. https://doi.org/10.1016/j.bioadv.2023.213557

Garg, S., Heuck, G., Ip, S. & Ramsay, E. 2016. Microfluidics: A transformational tool for nanomedicine development and production. *Journal of Drug Targeting* 24(9): 821-835. https://doi.org/10.1080/1061186X.2016.1198354

Gu, B., Han, K., Cao, H., Huang, X., Li, X., Mao, M., Zhu, H., Cai, H., Li, D. & He, J. 2024. Heart-on-a-chip systems with tissue-specific functionalities for physiological, pathological, and pharmacological studies. *Materials Today Bio* 24: 100914. https://doi.org/https://doi.org/10.1016/j.mtbio.2023.100914

Herland, A., van der Meer, A.D., FitzGerald, E.A., Park, T-E., Sleeboom, J.J.F. & Ingber, D.E. 2016. Distinct contributions of astrocytes and pericytes to neuroinflammation identified in a 3D human blood-brain barrier on a chip. *PLoS ONE* 11(3): e0150360. https://doi.org/10.1371/journal.pone.0150360

Hinton, T.J., Jallerat, Q., Palchesko, R.N., Park, J.H., Grodzicki, M.S., Shue, H-J., Ramadan, M.H., Hudson, A.R. & Feinberg, A.W. 2025. Three-dimensional printing of complex biological structures by freeform reversible embedding of suspended hydrogels. *Science Advances* 1(9): e1500758. https://doi.org/10.1126/sciadv.1500758

Huang, C., Sanaei, F., Verdurmen, W.P.R., Yang, F., Ji, W. & Walboomers, X.F. 2023. The application of organs-on-a-chip in dental, oral, and craniofacial research. *Journal of Dental Research* 102(4): 364-375. https://doi.org/10.1177/00220345221145555

Ionov, L. 2018. 4D biofabrication: Materials, methods, and applications. *Advanced Healthcare Materials* 7(17): 1800412. https://doi.org/https://doi.org/10.1002/adhm.201800412

Jeon, E.Y., Sorrells, L. & Abaci, H.E. 2022. Biomaterials and bioengineering to guide tissue morphogenesis in epithelial organoids. *Frontiers in Bioengineering and Biotechnology* 10: 1038277. https://doi.org/10.3389/fbioe.2022.1038277

Jia, S., Bu, Y., Lau, D-S.A., Lin, Z., Sun, T., Lu, W.W., Lu, S., Ruan, C. & Chan, C-H.J. 2023. Advances in 3D bioprinting technology for functional corneal reconstruction and regeneration. *Frontiers in Bioengineering and Biotechnology* 10: 1065460. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.1065460

Kahraman, E., Ribeiro, R., Lamghari, M. & Neto, E. 2022. Cutting-edge technologies for inflamed joints on chip: How close are we? *Frontiers in Immunology* 13: 802440. https://doi.org/10.3389/fimmu.2022.802440

Kang, H-W., Lee, S.J., Ko, I.K., Kengla, C., Yoo, J.J. & Atala, A. 2016. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. *Nature Biotechnology* 34(3): 312-319. https://doi.org/10.1038/nbt.3413

Kim, B.S., Lee, J-S., Gao, G. & Cho, D-W. 2017. Direct 3D cell-printing of human skin with functional transwell system. *Biofabrication* 9(2): 025034. https://doi.org/10.1088/1758-5090/aa71c8

Kim, M., Panagiotakopoulou, M., Chen, C., Ruiz, S.B., Ganesh, K., Tammela, T. & Heller, D.A. 2023. Micro-engineering and nano-engineering approaches to investigate tumour ecosystems. *Nature Reviews Cancer* 23: 581-599. https://doi.org/10.1038/s41568-023-00593-3

Kim, S., Chung, M., Ahn, J., Lee, S. & Jeon, N.L. 2016. Interstitial flow regulates the angiogenic response and phenotype of endothelial cells in a 3D culture model. *Lab Chip* 16(21): 4189-4199. https://doi.org/10.1039/C6LC00910G

Kim, Y.B., Lee, H. & Kim, G.H. 2016. Strategy to achieve highly porous/biocompatible macroscale cell blocks, using a collagen/genipin-bioink and an optimal 3D printing process. *ACS Applied Materials & Interfaces* 8(47): 32230-32240. https://doi.org/10.1021/acsami.6b11669

Kirillova, A. & Ionov, L. 2019. Shape-changing polymers for biomedical applications. *Journal of Materials Chemistry B* 7(10): 1597-1624. https://doi.org/10.1039/C8TB02579G

Klangprapan, J., Souza, G.R. & Ferreira, J.N. 2024. Bioprinting salivary gland models and their regenerative applications. *BDJ Open* 10: 39. https://doi.org/10.1038/s41405-024-00219-2

Klotz, B.J., Gawlitta, D., Rosenberg, A.J.W.P., Malda, J. & Melchels, F.P.W. 2016. Gelatin-methacryloyl hydrogels: Towards biofabrication-based tissue repair. *Trends in Biotechnology* 34(5): 394-407. https://doi.org/https://doi.org/10.1016/j.tibtech.2016.01.002

Kolesky, D.B., Homan, K.A., Skylar-Scott, M.A. & Lewis, J.A. 2016. Three-dimensional bioprinting of thick vascularized tissues. *Proceedings of the National Academy of Sciences* 113(12): 3179-3184. https://doi.org/10.1073/pnas.1521342113

Lam, E.H.Y., Yu, F., Zhu, S. & Wang, Z. 2023. 3D bioprinting for next-generation personalized medicine. *International Journal of Molecular Sciences* 24(7): 6357. https://doi.org/10.3390/ijms24076357

Li, H., Li, N., Zhang, H., Zhang, Y., Suo, H., Wang, L. & Xu, M. 2020. Three-dimensional bioprinting of perfusable hierarchical microchannels with alginate and silk fibroin double cross-linked network. *3D Printing and Additive Manufacturing* 7(2): 78-84. https://doi.org/10.1089/3dp.2019.0115

Lim, K.S., Levato, R., Costa, P.F., Castilho, M.D., Alcala-Orozco, C.R., van Dorenmalen, K.M.A., Melchels, F.P.W., Gawlitta, D., Hooper, G.J., Malda, J. & Woodfield, T.B.F. 2018. Bio-resin for high resolution lithography-based biofabrication of complex cell-laden constructs. *Biofabrication* 10(3): 034101. https://doi.org/10.1088/1758-5090/aac00c

Lin, H., Zhang, D., Alexander, P.G., Yang, G., Tan, J., Cheng, A.W-M. & Tuan, R.S. 2013. Application of visible light-based projection stereolithography for live cell-scaffold fabrication with designed architecture. *Biomaterials* 34(2): 331-339. https://doi.org/10.1016/j.biomaterials.2012.09.048

Liu, T., Weng, W., Zhang, Y., Sun, X. & Yang, H. 2020. Applications of gelatin methacryloyl (GelMA) hydrogels in microfluidic technique-assisted tissue engineering. *Molecules* 25(22): 5305. https://doi.org/10.3390/molecules25225305

Ma, J., Wang, Y. & Liu, J. 2018. Bioprinting of 3D tissues/organs combined with microfluidics. *RSC Advances* 8(39): 21712-21727. https://doi.org/10.1039/c8ra03022g

Makkar, H., Zhou, Y., Tan, K.S., Lim, C.T. & Sriram, G. 2023. Modeling crevicular fluid flow and host-oral microbiome interactions in a gingival crevice-on-chip. *Advanced Healthcare Materials* 12(6): 2202376. https://doi.org/https://doi.org/10.1002/adhm.202202376

Marcotulli, M., Tirelli, M.C., Volpi, M., Jaroszewicz, J., Scognamiglio, C., Kasprzycki, P., Karnowski, K., Święszkowski, W., Ruocco, G., Costantini, M., Cidonio, G. & Barbetta, A. 2023. Microfluidic 3D printing of emulsion ink for engineering porous functionally graded materials. *Advanced Materials Technologies* 8(5): 2201244. https://doi.org/https://doi.org/10.1002/admt.202201244

McDonald, J.C. & Whitesides, G.M. 2002. Poly(dimethylsiloxane) as a material for fabricating microfluidic devices. *Accounts of Chemical Research* 35(7): 491-499. https://doi.org/10.1021/ar010110q

Melchels, F.P.W., Feijen, J. & Grijpma, D.W. 2010. A review on stereolithography and its applications in biomedical engineering. *Biomaterials* 31(24): 6121-6130. https://doi.org/https://doi.org/10.1016/j.biomaterials.2010.04.050

Miao, S., Castro, N., Nowicki, M., Xia, L., Cui, H., Zhou, X., Zhu, W., Lee, S-J., Sarkar, K., Vozzi, G., Tabata, Y., Fisher, J. & Zhang, L.G. 2017. 4D printing of polymeric materials for tissue and organ regeneration. *Materials Today* 20(10): 577-591. https://doi.org/https://doi.org/10.1016/j.mattod.2017.06.005

Michas, C., Karakan, M.Ç., Nautiyal, P., Seidman, J.G., Seidman, C.E., Agarwal, A., Ekinci, K., Eyckmans, J., White, A.E. & Chen, C.S. 2025. Engineering a living cardiac pump on a chip using high-precision fabrication. *Science Advances* 8(16): eabm3791. https://doi.org/10.1126/sciadv.abm3791

Miri, A.K., Mostafavi, E., Khorsandi, D., Hu, S-K., Malpica, M. & Khademhosseini, A. 2019. Bioprinters for organs-on-chips. *Biofabrication* 11(4): 042002. https://doi.org/10.1088/1758-5090/ab2798

Moetazedian, A., Candeo, A., Liu, S., Hughes, A., Nasrollahi, V., Saadat, M., Bassi, A., Grover, L.M., Cox, L.R. & Poologasundarampillai, G. 2023. Versatile microfluidics for biofabrication platforms enabled by an agile and inexpensive fabrication pipeline. *Advanced Healthcare Materials* 12(26): 2300636. https://doi.org/10.1002/adhm.202300636

Moghimi, N., Ali Hosseini, S., Dalan, A.B., Mohammadrezaei, D., Goldman, A. & Kohandel, M. 2023. Controlled tumor heterogeneity in a co-culture system by 3D bio-printed tumor-on-chip model. *Scientific Reports* 13: 13648. https://doi.org/10.1038/s41598-023-40680-x

Monzón, M.D., Ortega, Z., Martínez, A. & Ortega, F. 2015. Standardization in additive manufacturing: Activities carried out by international organizations and projects. *The International Journal of Advanced Manufacturing Technology* 76(5): 1111-1121. https://doi.org/10.1007/s00170-014-6334-1

Muniraj, G., Tan, R.H.S., Dai, Y., Wu, R., Alberti, M. & Sriram, G. 2023. Microphysiological modeling of gingival tissues and host-material interactions using gingiva-on-chip. *Advanced Healthcare Materials* 12(32): 2301472. https://doi.org/10.1002/adhm.202301472

Murphy, S.V. & Atala, A. 2014. 3D bioprinting of tissues and organs. *Nature Biotechnology* 32(8): 773-785. https://doi.org/10.1038/nbt.2958

Ozbolat, I.T. & Hospodiuk, M. 2016. Current advances and future perspectives in extrusion-based bioprinting. *Biomaterials* 76: 321-343. https://doi.org/10.1016/j.biomaterials.2015.10.076

Park, T.E., Mustafaoglu, N., Herland, A., Hasselkus, R., Mannix, R., FitzGerald, E.A., Prantil-Baun, R., Watters, A., Henry, O., Benz, M., Sanchez, H., McCrea, H.J., Goumnerova, L.C., Song, H.W., Palecek, S.P., Shusta, E. & Ingber, D.E. 2019. Hypoxia-enhanced blood-brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies. *Nature Communications* 10(1): 2621. https://doi.org/10.1038/s41467-019-10588-0

Peired, A.J., Mazzinghi, B., De Chiara, L., Guzzi, F., Lasagni, L., Romagnani, P. & Lazzeri, E. 2020. Bioengineering strategies for nephrologists: Kidney was not built in a day. *Expert Opinion on Biological Therapy* 20(5): 467-480. https://doi.org/10.1080/14712598.2020.1709439

Petrosyan, A., Cravedi, P., Villani, V., Angeletti, A., Manrique, J., Renieri, A., De Filippo, R.E., Perin, L. & Da Sacco, S. 2019. A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. *Nature Communications* 10(1): 3656. https://doi.org/10.1038/s41467-019-11577-z

Pi, Q., Maharjan, S., Yan, X., Liu, X., Singh, B., van Genderen, A.M., Robledo-Padilla, F., Parra-Saldivar, R., Hu, N., Jia, W., Xu, C., Kang, J., Hassan, S., Cheng, H., Hou, X., Khademhosseini, A. & Zhang, Y.S. 2018. Digitally tunable microfluidic bioprinting of multilayered cannular tissues. *Advanced Materials* 30(43): 1706913. https://doi.org/10.1002/adma.201706913

Rose, S.C., Larsen, M., Xie, Y. & Sharfstein, S.T. 2024. Salivary gland bioengineering. *Bioengineering (Basel)* 11(1): 28. https://doi.org/10.3390/bioengineering11010028

Rothbauer, M., Eilenberger, C., Spitz, S., Bachmann, B.E.M., Kratz, S.R.A., Reihs, E.I., Windhager, R., Toegel, S. & Ertl, P. 2022. Recent advances in additive manufacturing and 3D bioprinting for organs-on-a-chip and microphysiological systems. *Frontiers in Bioengineering and Biotechnology* 2022: 3389. https://doi.org/10.3389/fbioe.2022.837087

Rothbauer, M., Bachmann, B.E.M., Eilenberger, C., Kratz, S.R.A., Spitz, S., Höll, G. & Ertl, P. 2021. A decade of organs-on-a-chip emulating human physiology at the microscale: A critical status report on progress in toxicology and pharmacology. *Micromachines* 12(5): 470. https://doi.org/10.3390/mi12050470

Serrano, D.R., Kara, A., Yuste, I., Luciano, F.C., Ongoren, B., Anaya, B.J., Molina, G., Diez, L., Ramirez, B.I., Ramirez, I.O., Sánchez-Guirales, S.A., Fernández-García, R., Bautista, L., Ruiz, H.K. & Lalatsa, A. 2023. 3D printing technologies in personalized medicine, nanomedicines, and biopharmaceuticals. *Pharmaceutics* 15(2): 313. https://doi.org/10.3390/pharmaceutics15020313

Shiwarski, D.J., Hudson, A.R., Tashman, J.W., Bakirci, E., Moss, S., Coffin, B.D. & Feinberg, A.W. 2024. 3D bioprinting of collagen-based microfluidics for engineering fully-biologic tissue systems. *bioRxiv* 2024.01.26.577422. https://doi.org/10.1101/2024.01.26.577422

Skardal, A., Devarasetty, M., Soker, S. & Hall, A.R. 2015. *In situ* patterned micro 3D liver constructs for parallel toxicology testing in a fluidic device. *Biofabrication* 7(3): 031001. https://doi.org/10.1088/1758-5090/7/3/031001

Sun, J., Yao, K., An, J., Jing, L., Huang, K. & Huang, D. 2023. Machine learning and 3D bioprinting. *International Journal of Bioprinting* 9(4): 717.

Terrell-Hall, T.B., Ammer, A.G., Griffith, J.I.G. & Lockman, P.R. 2017. Permeability across a novel microfluidic blood-tumor barrier model. *Fluids and Barriers of the CNS* 14: 3. https://doi.org/10.1186/s12987-017-0050-9

Tibbits, S. 2014. 4D Printing: Multi-material shape change. *Architectural Design* 84(1) (Special Issue: High Definition: Zero Tolerance in Design and Production): 116-121. https://doi.org/https://doi.org/10.1002/ad.1710

Ventura, R.D. 2021. An overview of laser-assisted bioprinting (LAB) in tissue engineering applications. *Medical Lasers* 10(2): 76-81. https://doi.org/10.25289/ml.2021.10.2.76

Vinson, B.T., Sklare, S.C. & Chrisey, D.B. 2017. Laser-based cell printing techniques for additive biomanufacturing. *Current Opinion in Biomedical Engineering* 2: 14-21. https://doi.org/10.1016/j.cobme.2017.05.005

Wang, D., Gust, M. & Ferrell, N. 2022. Kidney-on-a-chip: Mechanical stimulation and sensor integration. *Sensors* 22(18): 6889. https://doi.org/10.3390/s22186889

Wu, C.A., Zhu, Y. & Woo, Y.J. 2023. Advances in 3D bioprinting: Techniques, applications, and future directions for cardiac tissue engineering. *Bioengineering* 10(7): 842. https://doi.org/10.3390/bioengineering10070842

Wu, T., Gao, Y.Y., Su, J., Tang, X.N., Chen, Q., Ma, L.W., Zhang, J.J., Wu, J.M. & Wang, S.X. 2022. Three-dimensional bioprinting of artificial ovaries by an extrusion-based method using gelatin-methacryloyl bioink. *Climacteric* 25(2): 170-178. https://doi.org/10.1080/13697137.2021.1921726

Wu, Z., Cai, H., Ao, Z., Xu, J., Heaps, S. & Guo, F. 2021. Microfluidic printing of tunable hollow microfibers for vascular tissue engineering. *Advanced Materials Technologies* 6(8): 2000683. https://doi.org/10.1002/admt.202000683

Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., Guo, Q., Gao, X., Li, Y., Rao, X., Zhou, Y., Liang, L., Wang, Y., Zhang, J., Zhang, H., Li, G., Zhang, L., Peng, J., Cai, S., Hu, C., Gao, J., Clevers, H., Zhang, Z. & Hua, G. 2020. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. *Cell Stem Cell* 26(1): 17-26.e6. https://doi.org/10.1016/j.stem.2019.10.010

Yi, H.G., Lee, H. & Cho, D.W. 2017. 3D printing of organs-on-chips. *Bioengineering* 4(1): 10. https://doi.org/10.3390/bioengineering4010010

Zaeri, A., Zgeib, R., Cao, K., Zhang, F. & Chang, R.C. 2022. Numerical analysis on the effects of microfluidic-based bioprinting parameters on the microfiber geometrical outcomes. *Scientific Reports* 12(1): 3364. https://doi.org/10.1038/s41598-022-07392-0

Zandrini, T., Florczak, S., Levato, R. & Ovsianikov, A. 2023. Breaking the resolution limits of 3D bioprinting: Future opportunities and present challenges. *Trends in Biotechnology* 41(5): 604-614. https://doi.org/10.1016/j.tibtech.2022.10.009

Zhang, J., Chen, F., He, Z., Ma, Y., Uchiyama, K. & Lin, J-M. 2016. A novel approach for precisely controlled multiple cell patterning in microfluidic chips by inkjet printing and the detection of drug metabolism and diffusion. *Analyst* 141(10): 2940-2947. https://doi.org/10.1039/C6AN00395H

Zhang, J., Byers, P., Erben, A., Frank, C., Schulte-Spechtel, L., Heymann, M., Docheva, D., Huber, H.P., Sudhop, S. & Clausen-Schaumann, H. 2021. Single cell bioprinting with ultrashort laser pulses. *Advanced Functional Materials* 31(19): 2100066. https://doi.org/10.1002/adfm.202100066

Zhang, X., Yang, Y., Yang, Z., Ma, R., Aimaijiang, M., Xu, J., Zhang, Y. & Zhou, Y. 2023. Four-dimensional printing and shape memory materials in bone tissue engineering. *International Journal of Molecular Sciences* 24(1): 814. https://doi.org/10.3390/ijms24010814

Zhou, X., Wu, H., Wen, H. & Zheng, B. 2022. Advances in single-cell printing. *Micromachines* 13(1): 80. https://doi.org/10.3390/mi13010080

*Corresponding author; email: yuanzhenyabdp@126.com